Company news
Soleno Therapeutics, Inc. (NASDAQ:SLNO) news
Every Soleno Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Soleno Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)
May 7, 2026
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
May 5, 2026
Folia Health Launches “BRAVE-PWS” Study to Better Understand the Real-World Experience of Prader-Willi Syndrome Caregivers
April 15, 2026
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
April 6, 2026
Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer
February 25, 2026
Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR
February 25, 2026
Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET
February 11, 2026
Soleno Therapeutics to Participate in Upcoming Conferences
January 28, 2026
Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results
January 11, 2026
Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism
January 4, 2026
Soleno Therapeutics Announces the Passing of Board Member William G. Harris
December 2, 2025
Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
November 23, 2025
Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement
November 10, 2025
Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR
November 3, 2025
Soleno Therapeutics to Participate in Upcoming November Conferences
October 27, 2025
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
October 22, 2025
Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET
October 20, 2025
Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors
October 12, 2025
Soleno Therapeutics to Participate in Upcoming September Conferences
August 26, 2025
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results
August 5, 2025
Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET
July 27, 2025
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock
July 9, 2025
Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
July 9, 2025
Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025
July 9, 2025
Soleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ENDO 2025
June 30, 2025
Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference
June 24, 2025
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference
June 19, 2025
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome
May 21, 2025
Soleno Therapeutics to Participate in Upcoming June Conferences
May 20, 2025
Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome
May 20, 2025
Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader...
May 19, 2025
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025
May 15, 2025
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025
May 12, 2025
Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025
May 7, 2025
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results
May 6, 2025
Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET
April 22, 2025
Soleno Therapeutics Announces VYKAT(TM) XR Launch
April 13, 2025
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
March 25, 2025
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
February 26, 2025
Soleno Therapeutics to Participate in Upcoming February Investor Conferences
January 28, 2025
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC
December 16, 2024
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
November 25, 2024
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024
November 13, 2024
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
November 5, 2024
Soleno Therapeutics to Participate in Upcoming November Investor Conferences
October 27, 2024
Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.
October 20, 2024
Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome
October 7, 2024
Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference
September 15, 2024
Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
August 26, 2024